John Berriman
Director/Board Member at AUTOLUS THERAPEUTICS PLC
Net worth: 320 378 $ as of 30/12/2024
Profile
John Edward Berriman is the founder of Solexa Ltd.
He currently holds the position of Non-Executive Chairman at Autifony Therapeutics Ltd., Chairman at Depixus SAS, Non-Executive Director at Autolus Ltd., and Lead Independent Director at Autolus Therapeutics Plc.
Previously, he served as the Non-Executive Chairman at ReNeuron Group Plc from 2011 to 2020.
He also held the position of Executive Deputy Chairman at Oxxon Therapeutics, Inc. in 2006, Chairman at MyCartis NV, Deputy Chairman at Algeta ASA from 2004 to 2008, Chairman at Nxera Pharma UK Ltd.
from 2007 to 2015, Chairman at Confo Therapeutics NV from 2016 to 2023, Director at Celltech Group Plc from 1989 to 1996, Director at Abingworth Management Ltd.
from 1997 to 2004, Director at Abingworth LLP from 1997 to 2001, Non-Executive Director at Cytos Biotechnology AG in 2012, Director at Epigenomics AG in 2006, Director at Alnylam Pharmaceuticals, Inc. from 2003 to 2005, Director at Ablynx NV from 2004 to 2007, Director at Chroma Therapeutics Ltd., Director at Direct Conversion AB, Director at Amgen Rockville, Inc. from 2006 to 2012, and Director at Micromet Inc. He pursued his undergraduate studies at the University of Cambridge and obtained an MBA from London Business School.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
AUTOLUS THERAPEUTICS PLC
0.08% | 28/02/2024 | 136,331 ( 0.08% ) | 320 378 $ | 30/12/2024 |
Latest news about John Berriman
John Berriman active positions
Companies | Position | Start |
---|---|---|
AUTOLUS THERAPEUTICS PLC | Director/Board Member | 31/07/2014 |
Depixus SAS
![]() Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | Chairman | 30/11/2015 |
Autolus Ltd.
![]() Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Director/Board Member | - |
Autifony Therapeutics Ltd.
![]() Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Chairman | 22/08/2011 |
Former positions of John Berriman
Companies | Position | End |
---|---|---|
Confo Therapeutics NV
![]() Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Chairman | 28/08/2023 |
RENEURON GROUP PLC | Chairman | 09/09/2020 |
Nxera Pharma UK Ltd.
![]() Nxera Pharma UK Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Chairman | 31/01/2015 |
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Director/Board Member | - |
Micromet Inc. | Director/Board Member | 31/12/2011 |
Training of John Berriman
London Business School | Masters Business Admin |
University of Cambridge | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 4 |
---|---|
ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
EPIGENOMICS AG | Health Technology |
RENEURON GROUP PLC | Health Technology |
AUTOLUS THERAPEUTICS PLC | Health Technology |
Private companies | 18 |
---|---|
Amgen Rockville, Inc.
![]() Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
MyCartis NV
![]() MyCartis NV BiotechnologyHealth Technology MyCartis NV develops technologies for healthcare personalization needs. It offers Evalution, a multiplex analysis platform to develop protein and nucleic-acid based clinical biomarkers. The company provides disruptive solutions in the fields of clinical and translational research for various applications in the detection of proteins and nucleic acids, such as sandwich immunoassays, antibody assays, genotyping assays, and mutation analysis assays to customers and partners. It offers products for various disease areas, including cell signalling, cardiovascular, oncology, and preeclampsia. The company was founded by Koen Kas in August 2004 and is headquartered in Ghent, Belgium. | Health Technology |
Abingworth LLP
![]() Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Finance |
Solexa Ltd.
![]() Solexa Ltd. Medical SpecialtiesHealth Technology Solexa Ltd. was a developer of instruments for analyzing genes in the process of drug development. It's research methods have included DNA sequencing, gene expression, genotyping and micro-RNA analysis to allow scientists to analyze individual genomes for drug development and personalized medicine. The company was headquartered in Saffron Walden, UK. | Health Technology |
Chroma Therapeutics Ltd.
![]() Chroma Therapeutics Ltd. BiotechnologyHealth Technology Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Direct Conversion AB
![]() Direct Conversion AB Medical SpecialtiesHealth Technology Direct Conversion AB manufactures and supplies X-Ray detectors such as cadmium telluride (CdTe) detectors. The firm’s products are used in the dental, medical, welding, industrial, food and security industries. The company was founded in 1997 and is headquartered in Danderyd, Sweden. | Health Technology |
Nxera Pharma UK Ltd.
![]() Nxera Pharma UK Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |
Ablynx NV
![]() Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Celltech Group Plc
![]() Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Oxxon Therapeutics, Inc.
![]() Oxxon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Oxxon Therapeutics, Inc. develops and manufactures antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. The company has three development programs in hepatitis, melanoma, and HIV. Oxxon Therapeutics was founded in 1999 by Dr. Joerg Schneider and is located at Oxford, UK. | Health Technology |
Autifony Therapeutics Ltd.
![]() Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Cytos Biotechnology AG
![]() Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Commercial Services |
Autolus Ltd.
![]() Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Health Technology |
Confo Therapeutics NV
![]() Confo Therapeutics NV Pharmaceuticals: MajorHealth Technology Confo Therapeutics NV develops pharmaceutical products. It is a drug discovery company building internal drug discovery programs on GPCRs addressing unmet medical need. The company was founded by Jan Steyaert and Toon Laeremans in June 2015 and is headquartered in Brussels, Belgium. | Health Technology |
Depixus SAS
![]() Depixus SAS Miscellaneous Commercial ServicesCommercial Services Depixus SAS is a life science technology company based in Paris, France. Depixus is pioneering ground-breaking magna™ technology based on magnetic force spectroscopy, revealing dramatic new insights into complex biomolecular interactions at the single molecule level. The French company was founded by Gordon Hamilton and has been the CEO since incorporation. | Commercial Services |
Algeta ASA
![]() Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
Abingworth Management Ltd.
![]() Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Finance |
Micromet Inc. |
- Stock Market
- Insiders
- John Berriman